Leerink Partnrs Issues Negative Estimate for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.69) per share for the quarter, down from their previous forecast of ($0.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($2.01) EPS and FY2026 earnings at ($1.82) EPS.

ZNTL has been the subject of a number of other research reports. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. UBS Group cut their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Stock Down 12.6 %

Shares of ZNTL stock opened at $1.39 on Monday. The firm has a market capitalization of $99.82 million, a PE ratio of -0.56 and a beta of 1.75. The company has a 50 day moving average price of $2.01 and a 200-day moving average price of $2.83. Zentalis Pharmaceuticals has a 52 week low of $1.36 and a 52 week high of $16.21.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter.

Insiders Place Their Bets

In related news, insider Ingmar Bruns bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jan Skvarka purchased 60,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares in the last quarter. Verition Fund Management LLC lifted its stake in Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares during the period. SG Americas Securities LLC grew its holdings in Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after acquiring an additional 30,240 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $76,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.